ArcovaarcovaResources
Sign inStart for free
Resources/Biotech and pharma buying signals
Resources

Buying Signals for Biotech and Pharma Sales: Which Ones Actually Matter

Every buying signal tells you something different about an account. Funding, FDA milestones, a phase transition, hiring into the function you sell to, and a company expanding, growing headcount, opening a site, scaling a facility, point to new budget or new work forming. A publication or a conference badge tells you what a company and its people are actually working on right now, which is exactly the detail that sharpens a message once you know where to send it.

9 min readUpdated Jul 14, 2026

Key takeaways

  • Funding, FDA milestones, and hiring into your area often mean new budget, which is usually when work gets outsourced.
  • Expansion counts too: growing headcount, a new site, a facility scaling up.

You hear a lot of things called "signals": a LinkedIn post, a press release, a job posting, a conference badge. Each one tells you something different about an account. What you want is a read on which events point to new budget or new work forming, and which ones fill in the picture with the detail that makes a message land.

What counts as a buying signal in life science

The public events that matter for a life science account fall into a handful of categories, most of them specific to how biotech and pharma operate and get funded:

  • Capital. Funding rounds, grants, IPOs and follow-on raises, milestone payments.
  • Clinical and regulatory. Trial registrations, phase transitions, site expansions, FDA approvals, and designations like Fast Track, Breakthrough Therapy, and Priority Review.
  • People and hiring. Hiring into a specific function (CMC, clinical operations, regulatory, medical affairs, business development, commercial), executive hires, and individual job changes, promotions, and new-to-role moves.
  • Deals and direction. Partnerships, licensing deals, co-development agreements, M&A, commercialization moves.
  • Expansion. A new site, a facility scaling up, and steady headcount growth, all signs a company is taking on more than it can do alone.
  • Conference and visibility. A company exhibiting, or a contact presenting or attending a relevant industry conference. See selling around life science conferences for the full playbook on this category.
  • Research and IP. Publications and patent activity, showing what a company and its scientists are focused on right now.

Which ones to act on

Each entry above reveals something different about an account. Group them by what they point to, new money to spend, new work forming, or the detail that sharpens your message:

Act on: new budget or new work

Funding rounds, grants, and milestone payments put real money in the account. FDA approvals, phase transitions, and a new manufacturing facility create real new work that often needs outside help to get done, which is usually the point where it gets outsourced. Expansion belongs here too: a new site, a facility scaling up, or headcount growing steadily all say a company is taking on more than its current team can handle. Executive hiring into a function you sell to usually opens a fresh vendor re-evaluation. These are worth moving on.

Worth watching: change that points to a forming need

Hiring below the executive level into a relevant function, promotions and role changes for contacts you track, and partnership or licensing deals fall here. They say something is changing without proving a purchase is close, and they land hardest combined with another signal (see "signals compound" below).

Sharpens the message: research and visibility

A publication, a patent filing, or a contact attending a conference tells you what a company and its people are actually working on right now. That is exactly the detail that turns a generic outreach message into a specific one: the program, the technical angle, the show where you can meet them. Use it to sharpen a message you are already sending because of a budget or work signal above, not as the reason you prioritize the account in the first place.

Signals compound

Several signals appearing together, in related categories, is where confidence goes up, because it usually means the change is real and company-wide rather than a one-off: budget landing alongside a new need, or a strategy shift arriving with new people, is a stronger case than any single event alone. A single signal is already a real starting point; a cluster of them is what turns it into a confident, well-timed reason to reach out.

Read more on how these layer together, and how long each type of signal should stay relevant, in timing outreach with readiness signals.

Where Arcova fits: life science specific buying signals are genuinely hard to track by hand. Clinical trial registries, FDA databases, conference exhibitor and speaker lists, and hiring activity are scattered across dozens of public sources. Arcova watches these sources for accounts that already pass your fit criteria and rolls the raw events up into the categories above, so a rep sees "why now" instead of a wall of disconnected headlines.

For a fast, definitional reference to every signal type mentioned here, see the GTM signals glossary for life science sales.

Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →

Frequently asked questions

Is a company hiring always a buying signal?

No, the function matters more than the fact of hiring. A biotech hiring broadly across many departments is a general growth signal, but hiring into the specific function you sell into (CMC hiring for a manufacturing vendor, clinical operations hiring for a CRO, regulatory hiring for a compliance tool) is a much sharper indicator, because it points at exactly where the operational need is forming. Executive hiring into a relevant function is stronger still, since a new VP or C-suite hire usually opens a real vendor re-evaluation window.

What signals predict purchase readiness in biotech specifically?

The signals with the most direct line to a purchase decision are the ones tied to new budget (a funding round, a grant, a milestone payment) or newly created operational complexity (a clinical phase transition, an FDA milestone, a new manufacturing facility). These map to a real, near-term reason a company would need to buy something. Publications, patent filings, and general visibility do a different job: they tell you what a company and its people are focused on, which is what makes a well-timed message specific instead of generic.

What if a company shows a strong signal but is not a good fit?

It stays out of your working list. A strong signal at a company outside your ICP is interesting general market information, not a lead. Signals should only be evaluated for accounts that already pass your company and buyer fit checks; see how to prioritize accounts for the full model.

Which buying signal points to the fastest purchase decision in biotech and pharma?

A clinical phase transition, especially Phase 2 into Phase 3, usually points to the fastest purchase decision, because it means a company is committing a large new budget to a pivotal program and the operational complexity around it (trial sites, monitoring, manufacturing scale-up) just increased at the same time. A major funding round or an FDA approval reveal the same kind of momentum, for the same reason: each creates real, immediate new spending capacity or new operational need.

How is a buying signal different from generic web intent data?

Intent data usually tracks anonymous, aggregated research behavior, like a surge in searches for a product category, without tying it to a specific, verifiable event. A buying signal in the sense used here is a concrete, publicly documented event at a named company: a funding round, an FDA designation, a named hire. That specificity is what makes it usable in an actual outreach message, not just a directional heat map of who might be interested.

Do the same buying signals apply to medtech and diagnostics companies, not just biotech and pharma?

The categories mostly transfer, with different weight. Funding, hiring into a relevant function, executive hires, and facility or manufacturing expansion apply broadly across biotech, medtech, and diagnostics companies. Clinical and regulatory milestones matter for all of them too, though the specific pathway looks different for a device or diagnostic than it does for a drug. The underlying signal category is the more reliable thing to build a process around than any one milestone name.

Related reading

Guides

Prioritizing accounts: fit and readiness

A practical account prioritization framework for life science sales teams: gate on fit first, then use buying-readiness signals to decide when to act inside your best-fit list.

Guides

Timing outreach with readiness

When to reach out to a life science account, not just who to target: the readiness dimensions behind a buying signal, how quickly they should be acted on, and why they decay at different rates.

Reference

GTM signals glossary

Plain-language definitions of the fit, readiness, and buying-signal terms used in life science sales: from fit score and ICP to phase transitions, FDA milestones, and conference signals.

Guides

Selling around life science conferences

How to turn exhibitor, speaker, and attendee presence at BIO, ASCO, ASH, SITC, ESMO and other life science conferences into timed outreach, not a badge scan you follow up on weeks later.

See it on your own market

Score the accounts you already have against your ICP.

Bring in the data you already work with, from your CRM or the providers you already use, and Arcova scores it against your ICP, watches for the life science signals that matter, and tells you who is ready for outreach and why.

Start for free
HomeResourcesArcova SignalsCompareHelp centerPrivacyTermsContact
© 2026 Arcova. All rights reserved.